Genesis Biotechnology Group (GBG) is a consortium of an integrated group of biotechnology and research companies. Its acquisition of the preclinical Contract Research Organization (CRO) PharmOptima, adds to its existing drug development segment, which includes Invivotek and Venenum Biodesign.
Ben Bandaru, Ph.D., Director of Mergers & Acquisitions at GBG, told us it has a history of making acquisitions that add to its capabilities and expand its services.
“Ultimately, this addition gives our clients the ability to work with one provider for early discovery through pre-clinical candidate identification without sacrificing time or talent,” he said.
“PharmOptima services integrate into our current workflow to complete the discovery pathway providing assay and reagent development capabilities, ADME/PK and bioanalysis services that ultimately contribute to selection of a de-risked pre-clinical candidate.”
Additionally, PharmOptima brings expertise in the growing ophthalmology therapeutics field, which Buiakova said further enhances GBG’s services portfolio “to meet the growing market demand.”